Overactive bladder is a common condition that manifests as a complex set of symptoms in the lower urinary tract and affects both men and women. It is characterized by sudden urges to urinate and may be accompanied by urinary incontinence, urinary frequency, and/or nocturia (nighttime waking to void the bladder). In addition to possible lifestyle changes and/or behavior interventions to help manage overactive bladder, a step-up approach to treatment is generally followed. It typically begins with antimuscarinics, before progressing to more-potent drugs, such as the beta3 adrenergic receptor agonist Myrbetriq (Astellas) or the injectable neurotoxin Botox (Allergan).


  •  What patient shares do key therapies and brands garner by line of therapy in newly diagnosed overactive bladder patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed overactive bladder patients?
  •  How have Myrbetriq and Botox been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of overactive bladder patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of overactive bladder patients are treated with monotherapy versus combination therapy? What are the most common combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?



United States

Real-world data

Longitudinal patient-level claims data analysis

Key drugs covered

Botox, Myrbetriq, oral oxybutynin, tolterodine tartrate, trospium chloride, Vesicare

Key analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Overactive Bladder - Current Treatment - Treatment Algorithms Claims Data Analysis (US)
    • Treatment Algorithms: Claims Data Analysis - Overactive Bladder US PPT June 2019

Author(s): Ritesh Gupta, PhD

Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease.

He holds a Ph.D. degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.